University Health Network

Yi Yao

Miklos Feher

Yong Liu

Heinz W Pauls

Peter Brent Sampson

Radoslaw Laufer

Bryan T Forrest

Guohua Pan

Tak Wah Mak

Yunhui Lang

Kathrin Zaugg

A CPT1 inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. 

Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer

A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. 

Inhibitors of carnitine palmitoyltransferase and treating cancer

Growing community of inventors

Mississauga, Canada

Yi Yao